

**Table 1. Baseline Characteristics of the Patients, According to Cohort.**

Characteristic	10 mg/kg Every 2 Wk		10 mg/kg Every 3 Wk		2 mg/kg Every 3 Wk	Total (N=135)
	No Prior Ipilimumab (N=41)	Prior Ipilimumab (N=16)	No Prior Ipilimumab (N=24)	Prior Ipilimumab (N=32)	No Prior Ipilimumab (N=22)	
<i>number (percent)</i>						
<b>Sex</b>						
Male	23 (56)	9 (56)	16 (67)	17 (53)	14 (64)	79 (59)
Female	18 (44)	7 (44)	8 (33)	15 (47)	8 (36)	56 (41)
<b>Age (yr)</b>						
Mean	60.4	59.4	67	57.3	58.6	60.4
Range	25–94	29–87	37–87	32–77	30–79	25–94
<b>Race<sup>a</sup></b>						
Asian	0	0	2 (8)	0	0	2 (1)
White	41 (100)	16 (100)	22 (92)	32 (100)	22 (100)	133 (99)
<b>ECOG performance status<sup>†</sup></b>						
Unknown	1 (2)	0	0	0	0	1 (1)
0	32 (78)	13 (81)	18 (75)	21 (66)	13 (59)	97 (72)
1	8 (20)	3 (19)	6 (25)	11 (34)	9 (41)	37 (27)
<b>BRAF mutation status</b>						
Mutant	13 (32)	1 (6)	1 (4)	5 (16)	6 (27)	26 (19)
Nonmutant	23 (56)	14 (88)	21 (88)	21 (66)	14 (64)	93 (69)
Unknown	5 (12)	1 (6)	2 (8)	6 (19)	2 (9)	16 (12)
<b>Brain metastasis</b>						
Yes	3 (7)	3 (19)	0	4 (12)	2 (9)	12 (9)
No	38 (93)	13 (81)	24 (100)	28 (88)	20 (91)	123 (91)
<b>Lactate dehydrogenase</b>						
Normal	23 (56)	11 (69)	16 (67)	17 (53)	13 (59)	80 (59)
Elevated <sup>‡</sup>	13 (32)	5 (31)	6 (25)	7 (22)	5 (23)	36 (27)
Unknown	5 (12)	0	2 (8)	8 (25)	4 (18)	19 (14)
<b>M staging of extent of metastasis</b>						
MX	0	0	0	1 (3)	0	1 (1)
M0	7 (17)	2 (12)	2 (8)	3 (9)	1 (5)	15 (11)
M1a	1 (2)	3 (19)	6 (25)	3 (9)	1 (5)	14 (10)
M1b	11 (27)	3 (19)	7 (29)	5 (16)	2 (9)	28 (21)
M1c	20 (49)	8 (50)	9 (38)	18 (56)	18 (82)	73 (54)
Unknown	2 (5)	0	0	2 (6)	0	4 (3)
<b>Previous treatment<sup>§</sup></b>						
No prior systemic treatment	16 (39)	0	12 (50)	0	14 (64)	42 (31)
Immunotherapy, excluding ipilimumab	11 (27)	4 (25)	5 (21)	10 (31)	4 (18)	34 (25)
Chemotherapy	11 (27)	8 (50)	9 (38)	14 (44)	5 (23)	47 (35)
BRAF inhibitor	4 (10)	0	1 (4)	4 (12)	1 (5)	10 (7)

<sup>a</sup> Race was self-reported.

<sup>†</sup> An Eastern Cooperative Oncology Group (ECOG) performance status of 0 indicates that the patient is fully active, 1 that the patient is restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, and 2 that the patient is ambulatory and capable of all self-care but unable to carry out any work activities.

<sup>‡</sup> An elevated level was considered to be a level higher than the upper limit of the normal range.

<sup>§</sup> This category included treatments for advanced disease. The numbers may add up to more than 100% since a patient may have received more than one type of oncologic therapy.

**Table 1. Baseline Characteristics of the Patients, According to Cohort.**



Fullscreen